title: Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
abstract: The incidence and correlates of extrapyramidal symptoms (EPS) in neuroleptic treatment of schizophrenic patients have been reported for chronic patients but not for first-episode patients. We examined the incidence and correlates of extrapyramidal symptoms in a cohort of 70 treatment-naive patients who received fluphenazine at 20-40 mg/day for the first 10 weeks of treatment. Thirty-four percent of our sample developed parkinsonism, 18 percent developed akathisia, and 36 percent developed dystonia. Acute EPS were associated with greater baseline psychopathology. Acute EPS were also associated with better treatment outcome in terms of time to and level of remission. These findings suggest that the EPS response of neuroleptic-naive patients may differ from that of chronically ill patients and that acute EPS status may be an indicator of pharmacologic responsivity in this group.
authors.affiliation: Psychiatry Research Department, Hillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY 11004.
authors.forename: M H
authors.initials: MH
authors.lastname: Chakos
authors.forename: D I
authors.initials: DI
authors.lastname: Mayerhoff
authors.forename: A D
authors.initials: AD
authors.lastname: Loebel
authors.forename: J M
authors.initials: JM
authors.lastname: Alvir
authors.forename: J A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D005476:Fluphenazine